Detalhe da pesquisa
1.
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Lancet Oncol
; 25(2): 198-211, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38301689
2.
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Br J Cancer
; 128(2): 245-254, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36352028
3.
RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
Ann Surg Oncol
; 30(2): 792-801, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36400886
4.
Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014).
Br J Cancer
; 122(6): 749-758, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31932755
5.
Three-dimensional (3D) magnetic resonance volume assessment and loco-regional failure in anal cancer: early evaluation case-control study.
BMC Cancer
; 20(1): 1165, 2020 Nov 30.
Artigo
Inglês
| MEDLINE | ID: mdl-33256671
6.
Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression.
Future Oncol
; 16(28): 2177-2189, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32716216
7.
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 19(4): 562-578, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29611518
8.
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
Br J Cancer
; 119(11): 1332-1338, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30420616
9.
ASO Visual Abstract: RAS Mutation Status Should not be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
Ann Surg Oncol
; 30(2): 802-803, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36404378
10.
Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma.
Dis Colon Rectum
; 61(7): 795-802, 2018 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-29771808
11.
Management and grading of EGFR inhibitor-induced cutaneous toxicity.
Future Oncol
; 14(24): 2531-2541, 2018 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-29727211
12.
Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study.
Lancet Oncol
; 18(10): 1348-1359, 2017 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28802802
13.
The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer.
Eur Radiol
; 27(2): 607-617, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27090113
14.
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Lancet Oncol
; 17(2): 174-183, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26705854
15.
Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.
BMC Cancer
; 16: 523, 2016 07 25.
Artigo
Inglês
| MEDLINE | ID: mdl-27456697
16.
Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
J Clin Gastroenterol
; 48(5): 430-4, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24153157
17.
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Lancet Oncol
; 14(11): 1077-1085, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24028813
18.
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Lancet Oncol
; 14(6): 516-24, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23578724
19.
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
J Clin Invest
; 134(2)2024 Jan 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37934611
20.
Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
Eur J Cancer Care (Engl)
; 22(3): 413-9, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23527965